Zentalis Pharmaceuticals (ZNTL) to Release Quarterly Earnings on Wednesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) is anticipated to announce its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 21, 2026 at 4:00 PM ET.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Thursday, March 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.08). On average, analysts expect Zentalis Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zentalis Pharmaceuticals Stock Performance

NASDAQ:ZNTL opened at $4.14 on Tuesday. Zentalis Pharmaceuticals has a fifty-two week low of $1.13 and a fifty-two week high of $6.95. The stock has a market capitalization of $294.71 million, a P/E ratio of -2.18 and a beta of 1.99. The company’s 50-day simple moving average is $3.36 and its 200-day simple moving average is $2.44.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ZNTL. AQR Capital Management LLC boosted its stake in Zentalis Pharmaceuticals by 177.6% in the 1st quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock worth $985,000 after purchasing an additional 396,233 shares in the last quarter. Millennium Management LLC boosted its stake in Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after purchasing an additional 2,111,951 shares in the last quarter. Qube Research & Technologies Ltd acquired a new stake in Zentalis Pharmaceuticals in the 2nd quarter worth approximately $37,000. Sei Investments Co. boosted its stake in Zentalis Pharmaceuticals by 373.1% in the 2nd quarter. Sei Investments Co. now owns 167,100 shares of the company’s stock worth $194,000 after purchasing an additional 131,780 shares in the last quarter. Finally, Jane Street Group LLC raised its position in Zentalis Pharmaceuticals by 346.3% during the 2nd quarter. Jane Street Group LLC now owns 664,061 shares of the company’s stock worth $770,000 after buying an additional 515,257 shares during the last quarter.

Analyst Ratings Changes

A number of analysts have recently weighed in on ZNTL shares. Wells Fargo & Company started coverage on shares of Zentalis Pharmaceuticals in a report on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price target on the stock. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Guggenheim raised their price target on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a report on Friday, April 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $5.83.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.